Cagrilintide (5mg) / GLP-1 S (5mg) 

Mechanism of Action: How the Blend Works

This dual therapy acts on two key metabolic hormone pathways:

Cagrilintide (Amylin Analog)

• Slows gastric emptying for prolonged satiety
• Reduces hedonic eating and craving pathways
• Helps normalize post-meal glucose

GLP-1 S (GLP-1 RA)

• Enhances insulin response in a glucose-dependent manner
• Suppresses hunger signals via hypothalamic receptors
• May improve long-term metabolic efficiency

Together, they create a powerful appetite and glucose-control synergy superior to either pathway alone.

Clinical Dosing Guide for Providers

For licensed medical professionals only.

Suggested Dosage

• Initiation Range: 0.25–0.5mg weekly
• Therapeutic Range: 1–2.5mg weekly depending on patient response
• Cycle Duration: 12–30+ weeks depending on weight-management goals

Administration Notes

• Route: Subcutaneous injection
• Dosing frequency: Once weekly, flexible timing

Reconstitution & Storage

• Reconstitute using bacteriostatic water
• Refrigerate after mixing
• ~28-day stability refrigerated

Common Clinical Stacks

• AOD-9604 — increased fat-metabolism signaling
• GH Secretagogues — performance + recovery support
• BPC-157 — GI comfort during appetite transition

Ideal Candidate Profile

Potentially Good Candidates

• Individuals with chronic overeating or portion-control challenges
• Patients with metabolic resistance to diet alone
• Those who plateaued on GLP-1s and require next-tier appetite control
• Diabetic or pre-diabetic patients needing improved glycemic curves

Use With Caution

• Patients with pancreatitis risk — medical review required
• Severe gastrointestinal disorders
• Insulin-dependent diabetics — glucose monitoring required

Potential Side Effects

Generally mild and dose-dependent:

• Nausea or early-satiety discomfort
• Constipation or slowed GI transit
• Occasional fatigue
• Rare: vomiting if titrated too aggressively

Slow and steady escalation strongly reduces events.

Frequently Asked Questions

1. What does this blend do best?
Strong appetite reduction, improved portion control, and sustainable fat-loss support.

2. How fast does it start working?
Most patients notice reduced hunger within the first week.

3. Is it stronger than GLP-1 alone?
Yes — combining amylin + GLP-1 yields deeper satiety and fewer cravings.

4. Does it help blood sugar?
Yes — improves glucose handling and post-meal spikes.

5. Will I still enjoy food?
Yes — but food noise and compulsive eating typically decline.

6. Can it be used long term?
Often — ongoing review by the provider determines duration.

7. Do patients need strict dieting?
No, but better compliance often leads to better results.

8. Does it cause hypoglycemia?
Low risk due to glucose-dependent insulin stimulation.

9. Who should avoid this?
Individuals with active pancreatitis or severe GI dysmotility.

10. How is it stored?
Refrigerated after reconstitution.

Blend vs Similar Options

• Vs GLP-1 Alone:
  Significantly stronger appetite suppression + craving reduction.
• Vs Tirzepatide:
  This blend targets GLP-1 + Amylin, while tirzepatide targets GLP-1 + GIP — different metabolic focus.
• Vs Cagrilintide Alone:
  Improved glucose control and appetite synergy.

Research & Evidence Overview

Growing clinical literature supports dual incretin-pathway therapy for:

• Enhanced weight-management outcomes
• Improved glycemic stability
• Decreased overeating and compulsive food behavior
• Better satisfaction during caloric reduction

A next-generation approach to obesity and metabolic health support.

Product & Purity Assurance

99% purity standard

• Full COA + endotoxin screening
• cGMP pharmaceutical formulation
• Provider-restricted clinical dispensing

Legal & Medical Disclaimer

For licensed medical professionals only. Not intended to diagnose, treat, or cure any condition.